{"id":"NCT01976416","sponsor":"Indiana University","briefTitle":"Novel Use Of Hydroxyurea in an African Region With Malaria","officialTitle":"Novel Use Of Hydroxyurea in an African Region With Malaria","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-09","primaryCompletion":"2016-10","completion":"2017-11","firstPosted":"2013-11-05","resultsPosted":"2018-10-01","lastUpdate":"2018-12-04"},"enrollment":208,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Sickle Cell Anemia","Sickle Cell Disease","Malaria"],"interventions":[{"type":"DRUG","name":"Hydroxyurea","otherNames":["Siklos","Hydroxycarbamide"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Hydroxyurea","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"Multiple studies have shown that hydroxyurea has clinical efficacy in preventing acute painful episodes and reducing the need for blood transfusions in children with sickle cell anemia (SCA), but no study has been conducted in malaria endemic regions of sub-Saharan Africa, the areas with the most children with SCA.\n\nThe primary goal of this study is to investigate the safety and efficacy of hydroxyurea for children with SCA in a malaria endemic region within sub-Saharan Africa.","primaryOutcome":{"measure":"Number of Malaria Episodes","timeFrame":"12 months","effectByArm":[{"arm":"Hydroxyurea","deltaMin":5,"sd":null},{"arm":"Placebo","deltaMin":7,"sd":null}],"pValues":[]},"eligibility":{"minAge":"12 Months","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":5},"locations":{"siteCount":1,"countries":["Uganda"]},"refs":{"pmids":["29051184","40765704","31135090","27339303"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":6,"n":104},"commonTop":["Upper Respiratory Tract Infection","Vaso-Occlusive Crisis","Anemia","Pneumonia","Gastrointestinal-related"]}}